EACS 2025 was an essential meeting for the numerous presentations about PrEP that included far more than news about injectable formulations, which for all their promise, are still hardly used by anyone.
Cabotegravir-LA (CAB-LA) and lenacapavir…
Europe is missing HIV targets but EACS now recommends event-based PrEP for all using 2:1:1 or 2:7 dosing
